Ganeshan, Ramanan http://orcid.org/0000-0003-4043-1115
Betz, Manja
Scheitz, Jan F.
Erdur, Hebun
Audebert, Heinrich J.
Fiebach, Jochen B.
Villringer, Kersten
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 27 April 2021
Revised: 7 July 2021
Accepted: 8 July 2021
First Online: 17 July 2021
Declarations
:
: Jochen B Fiebach reports personal fees from Abbvie, AC Immune, Artemida, Bioclinica, Biogen, BMS, Brainomix, Cerevast, Daiichi-Sankyo, Eisai, F.Hoffmann-La Roche AG, Eli Lilly, Guerbet, Ionis Pharmaceuticals, IQVIA, Janssen, Julius clinical, jung diagnostics, Lysogene, Merck, Nicolab, Premier Research, Siemens, and Tau Rx, outside the submitted work. H. J. Audebert has received funding from the DFG, BMBF, Innovationsfonds, Future-Funds Berlin with cofounding of the European Union, Pfizer, and Stiftung Deutsche Schlaganfall-Hilfe. He has received speaker or consultancy honoraria from Boehringer Ingelheim, Siemens Healthcare, Pfizer, BMS, Bayer, Sanofi, Dayichi Sankyo, Ever Pharma, Lundbeck Pharma, and NovoNordisk. J.F.Scheitz reports grants from Corona-Stiftung and personal fees from W. L. Gore and Associates GmbH and Stryker GmbH & Co. KG, all outside the submitted work. The other authors declare no financial or other conflicts of interest.
: In accordance with laws and regulations of the Federal State of Berlin, this retrospective study did not require an ethics committee approval (§25 Landeskrankenhausgesetz).